Pharmacoépidémiologie cardiométabolique : Une évaluation de l'innocuité des médicaments à l'échelle populationnelle


Kristian Filion

Institut Lady Davis de recherches médicales de l'Hôpital général juif


Domaine : santé des populations

Programme chercheurs-boursiers - Junior 2

Concours 2017-2018

My research program focuses on the study of drug side effects.  Prescription drugs are tested extensively before they can be used in routine clinical practice. Despite this testing, side effects are common and may be life-threatening. Drug side effects cause over 100,000 deaths every year in North America. These side effects are not identified during testing because clinical trials usually include too few people for too short a time to find rare side effects. Also, people who participate in clinical trials may be different than those seen by doctors in a real world setting. 

For this reason, examining the medical records of large populations that are routinely collected by government and private health insurance plans plays an important role in studying the risks and benefits of prescription drugs. The goal of my research program is to identify preventable drug side effects. My program is particularly focused on drugs and side effects related to the heart and metabolic disorders such as diabetes. The first study will examine if the incretin-based drugs used to treat diabetes cause kidney problems. The second study will investigate if the pain killer tramadol causes heart problems and blood clots. The third study will determine if blood thinners increase the risk of kidney problems in patients with atrial fibrillation (an abnormal heartbeat).

A total of 88% of North Americans over the age of 60 years take at least 1 prescription drug. The study of the safety of prescription drugs is therefore needed to ensure individual and population health. My program will provide a platform to identify which drugs are safe and which ones are harmful. It will provide government agencies, health professionals, and patients with the information needed to make informed decisions. My program will therefore have direct clinical, public health, and policy implications.